RogerHideoKobayashiMDMS

PubMed

• Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
  Sudhir Gupta, James DeAngelo, Isaac Melamed, Jolan E Walter, Ai-Lan Kobayashi, Tracy Bridges, J Wesley Sublett, Jonathan A Bernstein, Alan Koterba, Michael Manning, Jo...> ;Journal of Clinical Immunology. 2023 Aug 1
• Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig]) in the treatment of patients with primary immu...
  Roger H Kobayashi, Sudhir Gupta, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kant...> ;Frontiers in Immunology. 2022 Jan 1
• 1 citations
  Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
  Sudhir Gupta, Roger H Kobayashi, Jiří Litzman, Laurel Cherwin, Sonja Hoeller, Huub Kreuwel> ;Expert Review of Clinical Immunology. 2023 Jan 1
• 3 citations
  Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
  Roger H Kobayashi, Jiří Litzman, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, T Prescott Atkinson, Syed Rehman, Sonja Höller, Eva Tu...> ;Clinical and Experimental Immunology. 2022 Dec 15
• An Updated Survey of SCID Outcomes Without Preconditioning Chemotherapy.
  Manish J Butte, Roger H Kobayashi> ;The Journal of Allergy and Clinical Immunology. in Practice. 2022 Apr 1
• 2 citations
  Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations.
  Roger H Kobayashi, Michael T Rigas> ;American Journal of Health-System Pharmacy. 2022 Aug 19
• 5 citations
  Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
  Roger H Kobayashi, Jiří Litzman, Syed Rizvi, Huub Kreuwel, Sonja Hoeller, Sudhir Gupta> ;Immunotherapy. 2022 Mar 1
• 4 citations
  Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]).
  Roger H. Kobayashi, Jose Fernando Mandujano, Syed M. Rehman, Ai Lan Kobayashi, Bob Geng, Thomas Prescott Atkinson, Isaac Melamed, Eva Turpel-Kantor, Elisabeth Clodi, S...> ;Immunotherapy. 2021 May 6
• 7 citations
  Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome.
  Isaac Melamed, Roger H. Kobayashi, Maeve O’Connor, Ai Lan Kobayashi, Andrew Schechterman, Melinda Heffron, Sharon Canterberry, Holly Miranda, Nazia Rashid> ;Journal of Child and Adolescent Psychopharmacology. 2021 Mar 15
• 15 citations
  Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
  Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed M. Rehman, Eva Turpel...> ;Frontiers in Immunology. 2019 Feb 4
• 10 citations
  Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.
  Hans D. Ochs, Isaac Melamed, Michael Borte, James N. Moy, Barbara Pyringer, Ai Lan D. Kobayashi, Alan P. Knutsen, William Smits, Anna Pituch-Noworolska, Roger H. Kobay...> ;Immunotherapy. 2018 Aug 8
• 15 citations
  Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective,...
  Isaac Melamed, Michael Borte, Laurenz Trawnicek, Ai-Lan Kobayashi, Roger H. Kobayashi, Alan P. Knutsen, Sudhir Gupta, William Smits, Anna Pituch-Noworolska, Magdalena ...> ;European Journal of Pharmaceutical Sciences. 2018 Jun 15
• 9 citations
  Dried Blood Spots, an Affordable Tool to Collect, Ship, and Sequence gDNA from Patients with an X-Linked Agammaglobulinemia Phenotype Residing in a Developing Country.
  Gesmar Rodrigues Silva Segundo, Anh Thi Van Nguyen, Huyen Thi Thanh Thuc, Le N. Q. Nguyen, Roger H. Kobayashi, Hai T. Le, Huong Thi Minh Le, Troy R. Torgerson, Hans D....> ;Frontiers in Immunology. 2018 Feb 16
• 6 citations
  Cost-effectiveness of using an extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in the US.
  Julian F. Guest, Roger H. Kobayashi, Vinay Mehta, Gary Neidich> ;Current Medical Research and Opinion. 2018 Sep 1
• 1 citations
  What Does Screening Newborns for T-Cell Lymphopenia Find?
  Sean A. McGhee, Roger H. Kobayashi> ;The Journal of Allergy and Clinical Immunology. in Practice. 2017 Sep 1
• 11 citations
  Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-...
  Michael Borte, Isaac Melamed, Grazyna Pulka, Barbara Pyringer, Alan P. Knutsen, Hans D. Ochs, Roger H. Kobayashi, Ai Lan Kobayashi, Sudhir Gupta, Magdalena Strach, Wil...> ;Journal of Clinical Immunology. 2017 Jul 29
• Back to the Future: 1753 - Vitamin C Remediates Scurvy, 2016 - Folinic Acid Does the Same for MTHFD1-SCID with the Help of Exome Sequencing
  Roger H. Kobayashi> ;The Journal of Allergy and Clinical Immunology. in Practice. 2016 Nov 1
• 20 citations
  Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses...
  Richard L. Wasserman, William R. Lumry, James B. Harris, Robyn J. Levy, Mark R. Stein, Lisa R. Forbes, Charlotte Cunningham-Rundles, Isaac Melamed, Ai Lan Kobayashi, W...> ;Journal of Clinical Immunology. 2016 Jun 20
• 28 citations
  Immunoglobulin G4–related sclerosing disease of the paranasal sinus
  Robert Lindau, Yungpo Bernard Su, Roger Kobayashi, Russell B. Smith> ;Head & Neck. 2012 Oct 10
• Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
  Gautam K. Malhotra, Roger H. Kobayashi, Jill A. Poole> ;The Israel Medical Association Journal. 2012 May 1
• 9 citations
  Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
  Haig Tcheurekdjian, Jamila Martin, Roger H. Kobayashi, Richard L. Wasserman, Robert Hostoffer> ;Allergy and Asthma Proceedings. 2006 Nov 1
• 49 citations
  Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment.
  Ulrike H.M. Ziegner, Roger H. Kobayashi, Charlotte Cunningham-Rundles, Teresa Espanol, Anders Fasth, Anna Huttenlocher, Paul Krogstad, Lars Marthinsen, Luigi D. Notara...> ;Clinical Immunology. 2002 Jan 1
• 44 citations
  Parvovirus B19-Induced Anemia as the Presenting Manifestation of X-Linked Hyper-IgM Syndrome
  Kuniaki Seyama, Roger H. Kobayashi, Henrik Hasle, Andrea J. Apter, Joe C. Rutledge, David A. Rosen, Hans D. Ochs> ;The Journal of Infectious Diseases. 1998 Aug 1
• 31 citations
  Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product
  E. Richard Stiehm, Adrian Casillas, Jerry Z. Finkelstein, Kerry Gallagher, Paula M. Groncy, Roger H. Kobayashi, James M. Oleske, Robert L. Roberts, Eric T. Sandberg, M...> ;The Journal of Allergy and Clinical Immunology. 1998 Jun 1
• 12 citations
  Exercise-induced asthma, anaphylaxis, and urticaria.
  Roger H. Kobayashi, Morris B. Mellion> ;Primary Care. 1991 Dec 1
• Join now to see all

Journal Articles

• Vol.:(0123456789)1 3Journal of Clinical Immunology https://doi.org/10.1007/s10875-023-01509-4 ORIGINAL ARTICLE Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary...  
  Sudhir Gupta1 · James DeAngelo2 · Isaac Melamed3 · Jolan E. Walter4 · Ai‑Lan Kobayashi5 · Tracy Bridges 6 · J. Wesley Sublett 7 · Jonathan A. Bernstein8 · Alan Koterba..., Journal of Clinical Immunology, 5/9/2023
• Long-term Efficacy, Safety, and Tolerability of a Subcutaneous Immunoglobulin 16.5% (cutaquig®) in the Treatment of Patients with Primary Immunodeficiencies  
  Roger H Kobayashi, Jiří Litzman, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, T Prescott Atkinson, Syed Rehman, Sonja Höller, et al., Clinical and Experimental Immunology Clinical and Experimental Immunology;, 10/8/2022
• Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome  
  Isaac Melamed, Roger H. Kobayashi, Maeve O'Connor, Ai Lan Kobayashi, Andrew Schechterman, Melinda Heffron, Sharon Canterberry, Holly Miranda, Nazia Rashid, Journal of Child and Adolescent Psychopharmacology, 2/18/2021
• Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies  
  Roger H. Kobayashi1*, Sudhir Gupta2, Isaac Melamed3, J. Fernando Mandujano4, Ai Lan Kobayashi5, Bruce Ritchie6, Bob Geng7, Thomas Prescott Atkinson8, Syed Rehm..., Front. Immunol., 04 February 2019, 2/3/2019
• Efficacy of human immunoglobulin 10% [Newgam] in Children with primary immunodeficiency diseases: subgroup analysis of a phase III multicenter, prospective, open label...  
  Ochs H, Melamed, Borte M, Moy J, Pyringer B, Kobayashi AD, Kobayashi RH, Knutsen, Immunotherapy. 2018, 8/8/2018
• Pharmacokinetics of a Novel High-Yield Human Intravenous Immunoglobulin 10% in Patients with Primary Immuno – deficiency Diseases; Analysis of a Phase III,Mu...  
  Melamed I, Borte M, Tranwnicek L, Moy J, Kobayashi A, Kobayashi RH, Ochs H, European J. Pharmaceutical Sci. 2018; 118:80 – 86, 6/15/2018
• Parvovirus B19-Induced Anemia as the Presenting Manifestation of X-Linked Hyper-IgM Syndrome  
  Seyama K, Kobayashi RH, Hasle H, Apter AJ, Rutledge JC, Rosen D, Ochs HD, Journal of Infectous Diseases, 8/1998
• Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses...  
  Richard L. Wasserman · William Lumry · James Harris · Robyn Levy · Roger Kobayashi, Journal of Clinical Immunology, 6/2016
• Immunoglobulin G4–related sclerosing disease of the paranasal sinus  
  Immunoglobulin G4–related sclerosing disease of the paranasal sinus Head & Neck Volum Robert H. Lindau, Yungpo Bernard Su, Roger Kobayashi and Russell B. Smith, Head and Neck, 10/2013
• Expert opinion regarding clinical and other outcome considerations in the formulatory review of immune globulin  
  Ricardo Sorensen, Chitra Dinakar, Ramsay Fuleihan, Sudhir Gupta, Alan Knutsen, Roger Kobayashi, Carol Lee Koski, Arnold I. Levinson, Ralph Shapiro, Richard L. Wasserman, Journal of Managed Care Pharmacy, 4/2007
• Octagam® 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases  
  Hans D. Ochs, Paul J. Pinciaro, Melvin Berger, Neil Kao, Jeffrey Kishiyama, Roger Kobayashi, William Shearer, Suzanne Skoda-Smith, William Smits, Mark Stein, Journal of Clinical Immunology, 5/2004
• Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product  
  Stiehm ER, Casillas AM, Finkelstein JZ, Gallagher KT, Gromcy PM, Kobayashi RH, Oleske JM, Roberts RL, Sandberg ET, Wakim ME, Journal of Allergy and Clinical Immunology, 6/1998
• Join now to see all